245 related articles for article (PubMed ID: 19386128)
1. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.
Chang DZ; Kumar V; Ma Y; Li K; Kopetz S
J Hematol Oncol; 2009 Apr; 2():18. PubMed ID: 19386128
[TBL] [Abstract][Full Text] [Related]
2. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
[TBL] [Abstract][Full Text] [Related]
3. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
Stintzing S; Heinemann V; Moosmann N; Hiddemann W; Jung A; Kirchner T
Dtsch Arztebl Int; 2009 Mar; 106(12):202-6. PubMed ID: 19471640
[TBL] [Abstract][Full Text] [Related]
4. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
De Stefano A; Carlomagno C
World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.
Siddiqui AD; Piperdi B
Ann Surg Oncol; 2010 Apr; 17(4):1168-76. PubMed ID: 19936839
[TBL] [Abstract][Full Text] [Related]
6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
8. Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.
Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
Biomed Res Int; 2014; 2014():591867. PubMed ID: 25032217
[TBL] [Abstract][Full Text] [Related]
9. Three different KRAS statuses in three synchronous colorectal cancers.
Jolissaint L; Cacheux W; Mariani P; Le Tourneau C; Lièvre A; Lappartient E; Margogne A; Farkhondeh F; de Cremoux P
Med Oncol; 2012 Dec; 29(4):2864-5. PubMed ID: 22467075
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.
Tímár J; Hegedüs B; Rásó E
Curr Cancer Drug Targets; 2010 Dec; 10(8):813-23. PubMed ID: 20718705
[TBL] [Abstract][Full Text] [Related]
11. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE; Kolesar JM; Vermeulen LC
Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
[TBL] [Abstract][Full Text] [Related]
13. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
van Krieken JH; Jung A; Kirchner T; Carneiro F; Seruca R; Bosman FT; Quirke P; Fléjou JF; Plato Hansen T; de Hertogh G; Jares P; Langner C; Hoefler G; Ligtenberg M; Tiniakos D; Tejpar S; Bevilacqua G; Ensari A
Virchows Arch; 2008 Nov; 453(5):417-31. PubMed ID: 18802721
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
16. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
Baas JM; Krens LL; Guchelaar HJ; Morreau H; Gelderblom H
Oncologist; 2011; 16(9):1239-49. PubMed ID: 21742964
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.
Tougeron D; Lecomte T; Pagès JC; Villalva C; Collin C; Ferru A; Tourani JM; Silvain C; Levillain P; Karayan-Tapon L
Ann Oncol; 2013 May; 24(5):1267-73. PubMed ID: 23293113
[TBL] [Abstract][Full Text] [Related]
18. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
PLoS One; 2014; 9(6):e99590. PubMed ID: 24940619
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutations: analytical considerations.
Herreros-Villanueva M; Chen CC; Yuan SS; Liu TC; Er TK
Clin Chim Acta; 2014 Apr; 431():211-20. PubMed ID: 24534449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]